$CNTB · Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States.
More about this company
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Not currently held by tracked 13F filers — this page aggregates activist, insider, politician and research activity.
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-04-01 | SCHEDULE 13D/A | Panacea Innovation Ltd | 21.2% | Med | filing |
| Filed | Insider | Role | Shares | Value | |
|---|
| 2026-04-01 | Huang James | director | 1,160,000 | $4,002,000 | Form 4 |